Product Information
ATAZANAVIR SULFATE 300 MG CAP is a generic product labeled by Camber Pharmaceuticals Inc., priced at $2.2264 per EA under NDC 31722065530. Its NADAC has been published 199 times since Oct 19, 2022.
FDA first approved this application on Feb 2, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722065530
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ATAZANAVIR SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA212278FDA Approved
2/2/2022
TE Code
AB
On Market Since
2/7/2022
Pharmacological Classes
Price Statistics
The NADAC for ATAZANAVIR SULFATE 300 MG CAP has been published 199 times since Oct 19, 2022, and over the history we have for it it has declined 36.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.2264 per EA |
|---|---|
| All-time high | $3.4956 (Feb 15, 2023) |
| All-time low | $1.7959 (Aug 21, 2024) |
| 52-week high | $3.0949 |
| 52-week low | $2.2264 |
| Median price | $3.3003 |
| Average price | $3.0082 |
| Largest weekly change | +41.4% (Oct 23, 2024) |
| Weeks tracked | 199 |
| Tracking since | Oct 19, 2022 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Atazanavir market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Protease Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ATAZANAVIR SULFATE 300 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for ATAZANAVIR SULFATE 300 MG CAP, manufactured by Camber Pharmaceuticals Inc., is $2.2264 per EA (NDC 31722065530), effective Sep 30, 2026.
How has the price of ATAZANAVIR SULFATE 300 MG CAP changed over time?
Over the history we have for it, the NADAC for ATAZANAVIR SULFATE 300 MG CAP has declined 36.3%. It has been tracked across 199 weekly CMS publications since Oct 19, 2022.
What are the highest and lowest recorded NADAC prices for ATAZANAVIR SULFATE 300 MG CAP?
Since Oct 19, 2022, the NADAC for ATAZANAVIR SULFATE 300 MG CAP has ranged from a low of $1.7959 (Aug 21, 2024) to a high of $3.4956 (Feb 15, 2023), with a median of $3.3003 per EA.
Are there cheaper alternatives to ATAZANAVIR SULFATE 300 MG CAP?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ATAZANAVIR SULFATE 300 MG CAP in a comparable dosage form, but none are currently priced below it.
Who manufactures ATAZANAVIR SULFATE 300 MG CAP?
ATAZANAVIR SULFATE 300 MG CAP (NDC 31722065530) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.